PILOT OF BUTHIONINE SULFOXIMINE WITH MELPHALAN IN NEUROBLASTOMA

神经母细胞瘤的治疗失败可能与获得性烷基化剂耐药性有关，烷基化剂的抗肿瘤作用可能通过用丁硫氨酸亚砜（BSO）消耗谷胱甘肽（GSH）而增强。本研究将评估（bso）和美法兰联合应用于小儿神经母细胞瘤患者的药代动力学和临床毒性。本研究的另一个目标是记录外周血淋巴细胞、正常骨髓和骨髓中发现的神经母细胞瘤细胞中的谷胱甘肽耗竭。

Treatment failure in neuroblastoma likely involves acquired alkylator resistance and the anti-tumor effect of alkylating agents may be increased by depletion of glutathione (GSH) with the drug buthionine sulfoximine (BSO). This study will evaluate the pharmacokinetics and clinical toxicities of the combination of (BS0) and melphalan in pediatric patients with neuroblastoma. An additional goal of this study is to document GSH depletion in peripheral blood lymphocytes, normal marrow and neuroblastoma cells found in the bone marrow.